The DOI matches its Crossref record; 258 of the 261 references it cites were found in a registry or an index.
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Open accessAbstract
Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the mechanisms underlying the plasma glucose level-lowering effects of metformin (1,1-dimethylbiguanide) still remain incompletely understood. Metformin is thought to exert its primary antidiabetic action through the suppression of hepatic glucose production. In addition, the discovery that metformin inhibits the mitochondrial respiratory chain complex 1 has placed energy metabolism and activation of AMP-activated protein kinase (AMPK) at the centre of its proposed mechanism of action. However, the role of AMPK has been challenged and might only account for indirect changes in hepatic insulin sensitivity. Various mechanisms involving alterations in cellular energy charge, AMP-mediated inhibition of adenylate cyclase or fructose-1,6-bisphosphatase 1 and modulation of the cellular redox state through direct inhibition of mitochondrial glycerol-3-phosphate dehydrogenase have been proposed for the acute inhibition of gluconeogenesis by metformin. Emerging evidence suggests that metformin could improve obesity-induced meta-inflammation via direct and indirect effects on tissue-resident immune cells in metabolic organs (that is, adipose tissue, the gastrointestinal tract and the liver). Furthermore, the gastrointestinal tract also has a major role in metformin action through modulation of glucose-lowering hormone glucagon-like peptide 1 and the intestinal bile acid pool and alterations in gut microbiota composition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A considerable number of studies have also found that metformin decreases fasting plasma glucose (PG) concentration and hemoglobin A1c by conserving the β-cell function or by decreasing liver glucose production (hepatic gluconeogenesis) (181–184).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [183]
Citations
Cites
Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics
Gibson, G. R., & Roberfroid, M. B. (1995) · Journal of Nutrition · doi:10.1093/jn/125.6.1401 · Cited by 7,659
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Gut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Cited by
Sorted by citations
Items 701–721 of 721
Maternal metformin treatment in obese pregnant dams normalizes neonatal sensory-motor reflexes
Müller-Limberger, E., Frederick, B., Hansen, S., Wohlfarth, M., Janoschek, R., Mahabir, E., Fischer, P., Gründemann, D., Kalis, S., Alcazar, M. A. A., et al. (2026) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-026-00259-8
Macrophage Immunometabolism in Epicardial Adipose Tissue and Obesity-Related Atrial Fibrillation
Xia, L., Sun, X., Xie, L., Liu, S., Phanaksri, T., Yu, Z., Jiang, Z., & Cao, X. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s640949
Fakorede, S., Lateef, O. M., Udefa, A. L., Ajagbe͓, A. O., Roy, S., Akosile, P. O., Awobona, T. A., & Anyanwu, G. E. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06237-5
Insulin signaling in PCOS/PMOS: molecular insights and clinical implications
Goel, A., Grover, A., & Shekhar, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1955884
Yin, Y., Chen, H., Xie, W., Wang, Y., Qian, Y., Sheng, R., Li, D., Li, J., Zhou, X., Dai, Z., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00521-6
Alimov, S., Tursunov, D., Sabirova, R., Турсунов, Д., Tursunov, D., & Sabirova, R. A. (2026) · Профилактическая медицина и здоровье · doi:10.47689/2181-3663-vol5-iss4-pp495-505
Beyond the Benefits: High-Dose Metformin and Emerging Metabolic Risks in type 2 diabetic patients
Moulai, K. (2025) · Journal of chemical health risks
Hepatic phospholipid remodeling in metabolic disorders
Tian, Y. (2023) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Fu, S., Zhou, F., Gong, L., & Ye, A. (2026) · Nutrition Research and Practice · doi:10.4162/nrp.2026.20.5.800
Fang, L., Li, X., Ban, R., Wang, C., Xu, Y., Xue, L., Shi, P., Sun, F., & Cao, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1927547
Wu, T., Yuan, R., Zheng, Z., Li, X., Liu, Z., Wang, J., He, M., Zhang, Y., Hu, Z., Tang, X., et al. (2026) · Liver Research · doi:10.1016/j.livres.2026.10.001
Patel, S. K., & Patil, J. K. (2026) · Asian Journal of Pharmacy and Technology · doi:10.52711/2231-5713.2026.00058
Oral hypoglycemic medications for GDM treatment
Lindsay, R. S., & Mackin, S. T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13265-0.00019-7
Yang, R., Zhang, S., Fu, Z., Yang, Y., Wang, Q., Zhou, Y., Li, J., Yang, R., Ning, S., Shi, Y., et al. (2026) · Medicinal Research Reviews · doi:10.1002/med.70117
NAWALE, S., Jadhav, D., Sayali, J., Hiranawale, S., & Sathe, M. (2026) · INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS · doi:10.56975/ijcrt.v14i10.401183
The AMPK signaling pathway in cell metabolism and human diseases
Zhang, Z., Gu, Y., He, H., Qiao, S., Shao, Y., 龙先铭, Huang, J., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02790-6
Метформин и микробиота кишечника
Николаевна, Г. И., Ивановна, Р. Т., Станиславовна, С. Т., & Львович, Н. Д. (n.d.) · CyberLeninK (CyberLeninka)
Toğuç, H., Ayçiçek, A., Tamar, D., Hökelek, B., & Özden, G. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1872938
Zhang, J., Li, Y., Xie, Y., Wang, R., Lai, L., Guo, B., & Tian, X. (2026) · Nano Letters · doi:10.1021/acs.nanolett.6c04272
Tanriverdi, A. M. (n.d.) · Marmara University Open Access System
Metadata
- Authors
- Foretz, M., Guigas, B., & Viollet, B.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Leiden University Medical Center (NL)
- Venue
- Nature Reviews Endocrinology
- Published
- 2019-08-22
- Volume
- 15
- Issue
- 10
- Pages
- 569-589
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W2969928163
- Cited by
- 686
- References
- 261
- Citations by year
- 2026: 80 · 2025: 104 · 2024: 92 · 2023: 122 · 2022: 113 · 2021: 102 · 2020: 68 · 2019: 5
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- green
- inserm.hal.science
- Licence
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- metformin, type 2 diabetes, glucoregulation, hepatic glucose production, gluconeogenesis, AMPK, mitochondrial complex I inhibition, hepatic insulin sensitivity, adenylate cyclase inhibition, FBP1, glycerol-3-phosphate dehydrogenase, redox state, meta-inflammation, obesity, gut microbiota, glucagon-like peptide-1, bile acids
- MeSH terms
- Gastrointestinal Microbiome, Animals, Diabetes Mellitus, Type 2, Electron Transport, Glucose, Humans, Hypoglycemic Agents, Metformin, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
